**Table S1: Risk of bias assessment of individual studies using PROBAST.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Participants** | | | | **Predictors** | | | **Outcome** | | | **Analysis** | | | **Overall** | | |
| **Cohort name** | **ROB** | **AC** | | | **ROB** | **AC** | | **ROB** | | **AC** | **ROB** | | | **ROB** | | **AC** |
| **1st Line Platinum/Chemotherapy** | | | | | | | | | | | | | | | | |
| Grossi 2017 | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Grossi 2018 (1) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Grossi 2018 (2) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| **2nd Line Chemotherapy** | | | | | | | | | | | | | | | | |
| Gregorc 2014 (1) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Fidler 2018 (1) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| **1st Line TKI** | | | | | | | | | | | | | | | | |
| Taguchi 2007 (1) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Stinchcombe 2013 (1) | unc | unc | | | low | low | | low | | low | low | | | **unc** | | **unc** |
| Mok 2016 | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Lee 2019 (1) | unc | unc | | | low | low | | low | | low | low | | | **unc** | | **unc** |
| **2nd Line TKI** | | | | | | | | | | | | | | | | |
| Taguchi 2007 (2) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Carbone 2012 (1) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Gregorc 2014 (2) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Gadgeel 2017 | unc | unc | | | low | low | | low | | low | low | | | **unc** | | **unc** |
| Buttigliero 2018 (1) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Fidler 2018 (2) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| **Best Supportive Care (BSC)** | | | | | | | | | | | | | | | | |
| Carbone 2012 (2) | low | | low | low | | low | low | | low | | | low | **low** | | **low** | |
| Lee 2019 (2) | unc | | unc | low | | low | low | | low | | | low | **unc** | | **unc** | |
| **Other (not meta-analyzed)** | | | | | | | | | | | | | | | | |
| Taguchi 2007 (3) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Taguchi 2007 (4) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Dingemans 2013 | unc | unc | | | low | low | | low | | low | low | | | **unc** | | **unc** |
| Kuiper 2012 | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Gautschi 2013 | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Stinchcombe 2013 (2) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |
| Buttigliero 2018 (2) | low | low | | | low | low | | low | | low | low | | | **low** | | **low** |

AC, applicability concerns; ROB, risk of bias; TKI, tyrosine kinase inhibitor; unc, unclear